

James E Polli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4920910/publications.pdf>

Version: 2024-02-01

137
papers

5,504
citations

101384

36
h-index

91712

69
g-index

140
all docs

140
docs citations

140
times ranked

4992
citing authors

#	ARTICLE	IF	CITATIONS
1	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2-13.	1.6	6
2	Evaluation of Excipient Risk in BCS Class I and III Biowaivers. <i>AAPS Journal</i> , 2022, 24, 20.	2.2	16
3	Lack of association between generic brittleness and neuropsychiatric measures in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2022, 128, 108587.	0.9	0
4	Prediction of In Vitro Drug Dissolution into Fed-state Biorelevant Media: Contributions of Solubility Enhancement and Relatively Low Colloid Diffusivity. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 173, 106179.	1.9	5
5	Sources of dissolution variability into biorelevant media. <i>International Journal of Pharmaceutics</i> , 2022, 620, 121745.	2.6	2
6	Prediction of in vitro drug dissolution into fasted-state biorelevant media: Contributions of solubility enhancement and relatively low colloid diffusivity. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 174, 106210.	1.9	6
7	Lack of an Effect of Polysorbate 80 on Intestinal Drug Permeability in Humans. <i>Pharmaceutical Research</i> , 2022, 39, 1881-1890.	1.7	7
8	Comparison of a single pharmaceutical surfactant versus intestinal biorelevant media for etravirine dissolution: Role and impact of micelle diffusivity. <i>International Journal of Pharmaceutics</i> , 2022, 624, 122015.	2.6	0
9	Characterization of Dissolution-Permeation System using Hollow Fiber Membrane Module and Utility to Predict in Vivo Drug Permeation Across BCS Classes. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 3075-3087.	1.6	3
10	Similarity of dissolution profiles from biorelevant media: Assessment of interday repeatability, interanalyst repeatability, and interlaboratory reproducibility using ibuprofen and ketoconazole tablets. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 156, 105573.	1.9	14
11	Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate. <i>Molecular Pharmaceutics</i> , 2021, 18, 1544-1557.	2.3	5
12	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1513-1526.	1.6	8
13	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1935-1947.	1.6	10
14	3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration. <i>Clinical and Translational Science</i> , 2021, 14, 1659-1680.	1.5	77
15	Research and Education Needs for Complex Generics. <i>Pharmaceutical Research</i> , 2021, 38, 1991-2001.	1.7	7
16	Metformin Disrupts Bile Acid Efflux by Repressing Bile Salt Export Pump Expression. <i>Pharmaceutical Research</i> , 2020, 37, 26.	1.7	16
17	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. <i>Molecular Pharmaceutics</i> , 2020, 17, 361-372.	2.3	13
18	The effects of spray drying, HPMCAS grade, and compression speed on the compaction properties of itraconazole-HPMCAS spray dried dispersions. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105556.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. <i>Pharmaceutics</i> , 2020, 12, 988.	2.0	12
20	Characterization of Grades of HPMCAS Spray Dried Dispersions of Itraconazole Based on Supersaturation Kinetics and Molecular Interactions Impacting Formulation Performance. <i>Pharmaceutical Research</i> , 2020, 37, 192.	1.7	13
21	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2654-2675.	1.6	7
22	Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy. <i>Pharmaceutical Research</i> , 2020, 37, 60.	1.7	1
23	Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2020, 105, 106936.	0.9	3
24	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1846-1862.	1.6	10
25	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3157-3168.	1.6	5
26	Utility of Films to Anticipate Effect of Drug Load and Polymer on Dissolution Performance from Tablets of Amorphous Itraconazole Spray-Dried Dispersions. <i>AAPS PharmSciTech</i> , 2019, 20, 331.	1.5	14
27	Fast liquid chromatography-tandem mass spectrometry method for simultaneous determination of eight antiepileptic drugs and an active metabolite in human plasma using polarity switching and timed selected reaction monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 176, 112816.	1.4	14
28	Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach. <i>Molecular Pharmaceutics</i> , 2019, 16, 1272-1281.	2.3	14
29	Pig gene mutation database. <i>Environmental and Molecular Mutagenesis</i> , 2019, 60, 759-762.	0.9	15
30	A 19F magnetic resonance imaging-based diagnostic test for bile acid diarrhea. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2019, 32, 163-171.	1.1	3
31	Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2019, 90, 197-203.	0.9	7
32	Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1). <i>Pharmaceutical Research</i> , 2018, 35, 14.	1.7	5
33	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1761-1772.	1.6	5
34	Attenuated Accumulation of Novel Fluorine (¹⁹ F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice. <i>Molecular Pharmaceutics</i> , 2018, 15, 4827-4834.	2.3	4
35	Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). <i>Pharmaceutical Research</i> , 2018, 35, 243.	1.7	24
36	Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. <i>Pharmaceutical Research</i> , 2018, 35, 204.	1.7	22

#	ARTICLE	IF	CITATIONS
37	Authorized Generic Drugs: an Overview. AAPS PharmSciTech, 2018, 19, 2450-2458.	1.5	5
38	Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice. Oncotarget, 2018, 9, 25572-25585.	0.8	20
39	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Journal of Pharmaceutical Sciences, 2017, 106, 1933-1943.	1.6	27
40	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate. Journal of Pharmaceutical Sciences, 2017, 106, 2930-2945.	1.6	31
41	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Folic Acid. Journal of Pharmaceutical Sciences, 2017, 106, 3421-3430.	1.6	19
42	Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey. Annals of the New York Academy of Sciences, 2017, 1407, 26-38.	1.8	9
43	Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. Toxicology and Applied Pharmacology, 2017, 314, 55-62.	1.3	19
44	Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs". Journal of Pharmaceutical Sciences, 2016, 105, 1355-1357.	1.6	5
45	Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. Journal of Pharmaceutical Sciences, 2016, 105, 996-1005.	1.6	43
46	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. Journal of Pharmaceutical Sciences, 2016, 105, 1362-1369.	1.6	17
47	Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs. International Journal of Pharmaceutics, 2016, 506, 110-115.	2.6	22
48	Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. Journal of Pharmaceutical Sciences, 2016, 105, 3243-3255.	1.6	23
49	Using Multi-fluorinated Bile Acids and <i>In Vivo</i> Magnetic Resonance Imaging to Measure Bile Acid Transport. Journal of Visualized Experiments, 2016, , .	0.2	6
50	Release of levetiracetam from extended-release tablets that appear intact in patient stool. Seizure: the Journal of the British Epilepsy Association, 2016, 40, 7-9.	0.9	2
51	Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metabolism and Disposition, 2016, 44, 489-494.	1.7	18
52	Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. Epilepsia, 2015, 56, 1415-1424.	2.6	68
53	Gordon L. Amidon: Very Sustained Drug Absorption. Journal of Pharmaceutical Sciences, 2015, 104, 2650-2663.	1.6	1
54	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine. Journal of Pharmaceutical Sciences, 2015, 104, 3289-3298.	1.6	31

#	ARTICLE	IF	CITATIONS
55	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2676-2687.	1.6	23
56	Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2864-2876.	1.6	19
57	Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets. <i>Molecular Pharmaceutics</i> , 2015, 12, 2436-2443.	2.3	25
58	Quantification of Lamotrigine in Patient Plasma Using a Fast Liquid Chromatography-Tandem Mass Spectrometry Method With Backflush Technology. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 188-197.	1.0	8
59	<i>Slc10a2</i> -null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. <i>Carcinogenesis</i> , 2015, 36, 1193-1200.	1.3	49
60	A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. <i>International Journal of Pharmaceutics</i> , 2015, 478, 88-95.	2.6	25
61	Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 66, 1-9.	1.9	29
62	Considerations for a Pediatric Biopharmaceutics Classification System (BCS): Application to Five Drugs. <i>AAPS PharmSciTech</i> , 2014, 15, 601-611.	1.5	35
63	The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3377-3397.	1.6	60
64	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fluconazole. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3843-3858.	1.6	29
65	Mechanistic interpretation of conventional Michaelis-Menten parameters in a transporter system. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 64, 44-52.	1.9	15
66	Structural Requirements of the Human Sodium-Dependent Bile Acid Transporter (hASBT): Role of 3- and 7-OH Moieties on Binding and Translocation of Bile Acids. <i>Molecular Pharmaceutics</i> , 2014, 11, 588-598.	2.3	5
67	<i>In Vivo</i> Performance of a Novel Fluorinated Magnetic Resonance Imaging Agent for Functional Analysis of Bile Acid Transport. <i>Molecular Pharmaceutics</i> , 2014, 11, 1575-1582.	2.3	20
68	Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver. <i>International Journal of Pharmaceutics</i> , 2014, 475, 597-604.	2.6	26
69	Design and Evaluation of a Novel Trifluorinated Imaging Agent for Assessment of Bile Acid Transport Using Fluorine Magnetic Resonance Imaging. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3782-3792.	1.6	10
70	Design and Characterization of a Novel Fluorinated Magnetic Resonance Imaging Agent for Functional Analysis of Bile Acid Transporter Activity. <i>Pharmaceutical Research</i> , 2013, 30, 1240-1251.	1.7	9
71	The solute carrier family 10 (SLC10): Beyond bile acid transport. <i>Molecular Aspects of Medicine</i> , 2013, 34, 252-269.	2.7	145
72	Structure-Activity Relationship for FDA Approved Drugs As Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP). <i>Molecular Pharmaceutics</i> , 2013, 10, 1008-1019.	2.3	86

#	ARTICLE	IF	CITATIONS
73	Phrygian Cap Appearance of a Mouse Gallbladder on Magnetic Resonance Imaging. <i>Journal of Veterinary Science & Medical Diagnosis</i> , 2013, 02, .	0.0	0
74	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Ketoprofen. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3593-3603.	1.6	70
75	A Substrate Pharmacophore for the Human Organic Cation/Carnitine Transporter Identifies Compounds Associated with Rhabdomyolysis. <i>Molecular Pharmaceutics</i> , 2012, 9, 905-913.	2.3	16
76	Putative Irreversible Inhibitors of the Human Sodium-Dependent Bile Acid Transporter (hASBT); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62. <i>Pharmaceutical Research</i> , 2012, 29, 1821-1831.	1.7	6
77	Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 46, 86-99.	1.9	30
78	Identification of Novel Nonsteroidal Compounds as Substrates or Inhibitors of hASBT. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 116-126.	1.6	8
79	Synthesis and In Vitro Evaluation of Gabapentin Prodrugs that Target the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT). <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 1184-1195.	1.6	33
80	Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3802-3816.	1.6	16
81	Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach. <i>Current Computer-Aided Drug Design</i> , 2011, 7, 10-22.	0.8	210
82	In Vivo Magnetic Resonance Imaging to Detect Biliary Excretion of 19F-Labeled Drug in Mice. <i>Drug Metabolism and Disposition</i> , 2011, 39, 736-739.	1.7	6
83	Comparison of Drug Permeabilities and BCS Classification: Three Lipid-Component PAMPA System Method versus Caco-2 Monolayers. <i>AAPS Journal</i> , 2010, 12, 238-241.	2.2	38
84	Quantitative Structure Activity Relationship for Inhibition of Human Organic Cation/Carnitine Transporter. <i>Molecular Pharmaceutics</i> , 2010, 7, 2120-2131.	2.3	31
85	Impact of Biopharmaceutics Classification System-Based Biowaivers. <i>Molecular Pharmaceutics</i> , 2010, 7, 1539-1544.	2.3	42
86	Effects of Commonly Used Excipients on the Expression of CYP3A4 in Colon and Liver Cells. <i>Pharmaceutical Research</i> , 2010, 27, 1703-1712.	1.7	27
87	Reliability of Inhibition Models to Correctly Identify Type of Inhibition. <i>Pharmaceutical Research</i> , 2010, 27, 2433-2445.	1.7	15
88	Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 43-52.	1.9	22
89	Why we should be vigilant: Drug cytotoxicity observed with in vitro transporter inhibition studies. <i>Biochemical Pharmacology</i> , 2010, 80, 1087-1092.	2.0	11
90	Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT. <i>International Journal of Pharmaceutics</i> , 2010, 396, 111-118.	2.6	24

#	ARTICLE	IF	CITATIONS
91	Targeting Drug Transporters – Combining In Silico and In Vitro Approaches to Predict In Vivo. <i>Methods in Molecular Biology</i> , 2010, 637, 65-103.	0.4	17
92	Structural Requirements of the ASBT by 3D-QSAR Analysis Using Aminopyridine Conjugates of Chenodeoxycholic Acid. <i>Bioconjugate Chemistry</i> , 2010, 21, 2038-2048.	1.8	15
93	Molecular Switch Controlling the Binding of Anionic Bile Acid Conjugates to Human Apical Sodium-Dependent Bile Acid Transporter. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4749-4760.	2.9	23
94	Structural Determinants for Transport across the Intestinal Bile Acid Transporter Using C-24 Bile Acid Conjugates. <i>Molecular Pharmaceutics</i> , 2010, 7, 2240-2254.	2.3	22
95	Uptake of Pramipexole by Human Organic Cation Transporters. <i>Molecular Pharmaceutics</i> , 2010, 7, 1342-1347.	2.3	27
96	Inhibition Requirements of the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT) Using Aminopiperidine Conjugates of glutamyl-Bile Acids. <i>Pharmaceutical Research</i> , 2009, 26, 1665-1678.	1.7	26
97	Novel Inhibitors of Human Organic Cation/Carnitine Transporter (hOCTN2) via Computational Modeling and In Vitro Testing. <i>Pharmaceutical Research</i> , 2009, 26, 1890-1900.	1.7	36
98	Computational Models for Drug Inhibition of the Human Apical Sodium-Dependent Bile Acid Transporter. <i>Molecular Pharmaceutics</i> , 2009, 6, 1591-1603.	2.3	89
99	The Use of BDDCS in Classifying the Permeability of Marketed Drugs. <i>Pharmaceutical Research</i> , 2008, 25, 483-488.	1.7	124
100	In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms. <i>AAPS Journal</i> , 2008, 10, 289-299.	2.2	117
101	Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond. <i>AAPS Journal</i> , 2008, 10, 373-379.	2.2	55
102	Method to Screen Substrates of Apical Sodium-Dependent Bile Acid Transporter. <i>AAPS Journal</i> , 2008, 10, 596-605.	2.2	16
103	Impact of Impurity on Kinetic Estimates from Transport and Inhibition Studies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 296-305.	1.3	6
104	Bias in Estimation of Transporter Kinetic Parameters from Overexpression Systems: Interplay of Transporter Expression Level and Substrate Affinity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 133-144.	1.3	32
105	Evaluation of a novel tablet splitter. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2007, 47, 185-187.	0.7	1
106	Computational Models to Assign Biopharmaceutics Drug Disposition Classification from Molecular Structure. <i>Pharmaceutical Research</i> , 2007, 24, 2249-2262.	1.7	61
107	Chemical Substituent Effect on Pyridine Permeability and Mechanistic Insight from Computational Molecular Descriptors. <i>Molecular Pharmaceutics</i> , 2006, 3, 745-755.	2.3	10
108	Rapid Identification of P-glycoprotein Substrates and Inhibitors. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1976-1984.	1.7	136

#	ARTICLE	IF	CITATIONS
109	Apical Sodium Dependent Bile Acid Transporter (ASBT, SLC10A2): A Potential Prodrug Target. <i>Molecular Pharmaceutics</i> , 2006, 3, 223-230.	2.3	150
110	Influence of Charge and Steric Bulk in the C-24 Region on the Interaction of Bile Acids with Human Apical Sodium-Dependent Bile Acid Transporter. <i>Molecular Pharmaceutics</i> , 2006, 3, 282-292.	2.3	24
111	Interaction of Native Bile Acids with Human Apical Sodium-Dependent Bile Acid Transporter (hASBT): Influence of Steroidal Hydroxylation Pattern and C-24 Conjugation. <i>Pharmaceutical Research</i> , 2006, 23, 1451-1459.	1.7	50
112	Lipid composition effect on permeability across PAMPA. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 29, 259-268.	1.9	50
113	Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. <i>Journal of Controlled Release</i> , 2006, 116, 50-57.	4.8	25
114	Development of Stably Transfected Monolayer Overexpressing the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT). <i>Pharmaceutical Research</i> , 2005, 22, 1269-1280.	1.7	41
115	Surfactant-mediated dissolution: Contributions of solubility enhancement and relatively low micelle diffusivity. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2064-2075.	1.6	116
116	Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. <i>Molecular Pharmaceutics</i> , 2004, 1, 40-48.	2.3	110
117	Human Intestinal Cellular Characteristics and Drug Permeability. , 2004, , 163-180.		2
118	Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. <i>Pharmaceutical Research</i> , 2003, 20, 757-764.	1.7	63
119	Characterization of Dexloxiglumide in vitro Biopharmaceutical Properties and Active Transport. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1968-1980.	1.6	11
120	Weight Uniformity of Split Tablets Required by a Veterans Affairs Policy. <i>Journal of Managed Care Pharmacy</i> , 2003, 9, 401-407.	2.2	39
121	Novel Metrics to Compare Dissolution Profiles. <i>Pharmaceutical Development and Technology</i> , 2002, 7, 257-265.	1.1	6
122	Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. <i>European Journal of Pharmaceutical Sciences</i> , 2002, 16, 237-246.	1.9	439
123	Biopharmaceutics classification system: the scientific basis for biowaiver extensions. <i>Pharmaceutical Research</i> , 2002, 19, 921-925.	1.7	460
124	Effect of Common Excipients on Caco-2 Transport of Low-Permeability Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1776-1786.	1.6	167
125	Novel direct curve comparison metrics for bioequivalence. , 2001, 18, 734-741.		24
126	Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. <i>International Journal of Pharmaceutics</i> , 2000, 200, 41-51.	2.6	77

#	ARTICLE	IF	CITATIONS
127	Influence of passive permeability on apparent P-glycoprotein kinetics. <i>Pharmaceutical Research</i> , 2000, 17, 1456-1460.	1.7	111
128	Prediction of dissolution-â€œabsorption relationships from a dissolution/Caco-2 system. <i>International Journal of Pharmaceutics</i> , 1999, 177, 117-125.	2.6	73
129	Dependence of In Vitro-In Vivo Correlation Analysis Acceptability on Model Selections. <i>Pharmaceutical Development and Technology</i> , 1999, 4, 89-96.	1.1	9
130	Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system. <i>AAPS PharmSci</i> , 1999, 1, 27-38.	1.3	52
131	Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. , 1998, 15, 47-52.		36
132	in Vitro-in Vivo Relationships of Several â€œImmediateâ€•Release Tablets Containing a Low Permeability Drug. <i>Advances in Experimental Medicine and Biology</i> , 1997, 423, 191-198.	0.8	20
133	Methods to Compare Dissolution Profiles and a Rationale for Wide Dissolution Specifications for Metoprolol Tartrate tabletsâ€•. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 690-700.	1.6	266
134	Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence. , 1997, 14, 1363-1369.		22
135	â€œPAVLOVIANâ€™ FOOD EFFECT ON THE ENTEROHEPATIC RECIRCULATION OF PIROXICAM. , 1996, 17, 635-641.		16
136	Novel Approach to the Analysis of in Vitroâ€œin Vivo Relationships**Presented in part at the Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, San Diego, CA, November 1994.. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 753-760.	1.6	76
137	Methods to Compare Dissolution Profiles. <i>Drug Information Journal</i> , 1996, 30, 1113-1120.	0.5	36